---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-023571"
form_type: "8-K"
ticker: "ORMP"
cik: "0001176309"
company_name: "ORAMED PHARMACEUTICALS INC."
filed_at: "2024-03-18T23:59:59+00:00"
generated_at: "2026-06-04T14:34:20.438885+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Oramed enters $75M at-the-market equity facility, terminates prior Cantor agreement

## Summary
- ATM agreement with Rodman & Renshaw and StockBlock Securities for up to $75M of common stock.
- Prior Cantor Fitzgerald ATM (up to $100M) terminated March 17, 2024; net proceeds from it were ~$26.25M.
- Agents receive 3.0% commission on gross proceeds; Company has no obligation to sell shares.

## SEC filing metadata
- accession: 0001213900-24-023571
- form_type: 8-K
- ticker: ORMP
- cik: 0001176309
- company_name: ORAMED PHARMACEUTICALS INC.
- filed_at: 2024-03-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1176309/000121390024023571/0001213900-24-023571-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1176309/000121390024023571/ea0201743-8k_oramed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-023571
- JSON: https://secwatch.observer/filing/0001213900-24-023571.json
- Plain text: https://secwatch.observer/filing/0001213900-24-023571.txt

## Key facts
- Material Agreements
  ORAMED PHARMACEUTICALS INC. terminated Controlled Equity Offering Agreement with Cantor Fitzgerald & Co. valued at Terminated with no penalties; prior net proceeds of $26.25 million (effective 2024-03-17).
  - Action: termination
  - Agreement: equity purchase
  - Counterparty: Cantor Fitzgerald & Co.
  - Value: Terminated with no penalties; prior net proceeds of $26.25 million
  - Effective: 2024-03-17
  source text: On March 12, 2024, the Company delivered written notice to Cantor Fitzgerald & Co. (“Cantor Fitzgerald”) to terminate that certain Controlled Equity Offering Agreement, dated September 1, 2021, by and between the Company and Cantor Fitzgerald (the “Cantor Agreement”), effective as of March 17, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1176309/000121390024023571/0001213900-24-023571-index.htm
- Material Agreements
  ORAMED PHARMACEUTICALS INC. entered into ATM Agreement with Rodman & Renshaw LLC and StockBlock Securities LLC valued at $75,000,000 maximum aggregate offering price (effective 2024-03-18).
  - Action: entry
  - Agreement: atm program
  - Counterparty: Rodman & Renshaw LLC and StockBlock Securities LLC
  - Value: $75,000,000 maximum aggregate offering price
  - Effective: 2024-03-18
  source text: On March 18, 2024, Oramed Pharmaceuticals Inc. (the “Company”) entered into an at the market offering agreement (the “ATM Agreement”) with Rodman & Renshaw LLC and StockBlock Securities LLC as sales agents (each, an “Agent” and together, the “Agents”), pursuant to which the Company may issue and sell in transactions that are deemed to be “at the market” offerings as defined in Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”), shares of its common stock, par value $0.012 per share, having a maximum aggregate offering price of up to $75,000,000 from time to time through the Agents.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1176309/000121390024023571/0001213900-24-023571-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.